NJC
Letter
3 R. W. Stephens, L. A. Domeier, M. G. Todd and V. A. Nelson,
Tetrahedron Lett., 1992, 33, 733.
4 (a) A. Donetti, A. Omodei-Sale, A. Mantegani and E. Zugna,
Tetrahedron Lett., 1969, 39, 3327; (b) G. Pala, A. Mantegani and
E. Zugna, Tetrahedron Lett., 1970, 26, 1275; (c) A. C. Currie,
G. T. Newbold and F. S. Spring, J. Chem. Soc., 1961, 4693.
5 (a) G. Kaupp, J. Schmeyers and J. Boy, Chem. – Eur. J., 1998,
4, 2467; (b) R. Sato, K. Itoh, H. Nishina, T. Goto and
M. Saito, Chem. Lett., 1984, 1913; (c) S. A. Bakunov, A. V.
Rukavishnikov and A. V. Tkachev, Synthesis, 2000, 1148;
(d) C.-Y. Chen, F. F. Wong, J. J. Huang, S.-K. Lin and
M.-Y. Yeh, Tetrahedron Lett., 2008, 49, 6505; (e) K. H.
Chaudhuri, U. S. Mahajan, D. S. Bhalerao and K. G.
Akamanchi, Synlett, 2007, 2815.
Scheme 2 Proposed mechanism.
6 (a) I. P. Beletskaya and A. V. Cheprakov, Coord. Chem. Rev.,
2004, 248, 2337; (b) J. F. Hartwig, Synlett, 2006, 1283;
(c) S. V. Ley and A. W. Thomas, Angew. Chem., Int. Ed.,
2003, 42, 5400–5449; (d) J.-P. Corbet and G. Mignani, Chem.
Rev., 2006, 106, 2651; (e) G. Evano, N. Blanchard and
M. Toymi, Chem. Rev., 2008, 108, 3054; ( f ) T. Kondo and
T.-A. Mitsudo, Chem. Rev., 2000, 100, 3205; (g) T. A. Choi,
R. Czerwonka, R. Forke, A. Jaeger, J. Knoell, M. P. Krahl,
T. Krause, K. R. Reddy, S. G. Franzblau and H.-J. Knoelker,
Table 2 Copper contamination in our catalyst (iron source)
S. no.
Sample
Absorbance of copper
1
2
3
4
5
6
Blank solution
0.0000
0.0000
0.0000
0.0000
0.0000
0.0000
Sample solution-1 (1 ppm)
Sample solution-2 (0.5 ppm)
Sample solution-3 (0.25 ppm)
Sample solution-4 (0.1 ppm)
Sample solution-5 (0.01 ppm)
´
Med. Chem. Res., 2008, 17, 374; (h) A. Correa, O. Garcıa
˜
Mancheno and C. Bolm, Chem. Soc. Rev., 2008, 37, 1108;
Conclusions
(i) F. Monnier and M. Taillefe, Angew. Chem., Int. Ed., 2009,
48, 6954; ( j) S. Wu¨rtz and F. Glorius, Acc. Chem. Res., 2008,
41, 1523.
In conclusion, we have developed a methodology for the synthesis
of 2-arylthio arylcyanamides using a cheap and readily available
iron source as a catalyst under mild reaction conditions. All the
substrates reacted under the optimized reaction conditions to
afford the desired products in good to high yield.
7 (a) N. Zheng, J. C. McWilliams, F. J. Fleitz, J. D. Armstrong
and R. P. Volante, J. Org. Chem., 1998, 63, 9606–9607;
(b) M. A. Fernandez-Rodriguez, Q. Shen and J. F. Hartwig,
J. Am. Chem. Soc., 2006, 128, 2180–2181; (c) G. Y. Li, Angew.
Chem., Int. Ed., 2001, 40, 1513–1516; (d) G. Y. Li, G. Zheng
and A. F. Noonan, J. Org. Chem., 2001, 66, 8677–8681;
(e) X. Lv and W. Bao, J. Org. Chem., 2007, 72, 3863–3867;
( f ) E. Sperotto, G. P. M. van Klink, J. G. de Vries and G. van
Koten, J. Org. Chem., 2008, 73, 5625–5628; (g) L. Rout,
P. Saha, S. Jammi and T. Punniyamurthy, Eur. J. Org. Chem.,
2008, 640–643; (h) L. Rout, T. K. Sen and T. Punniyamurthy,
Angew. Chem., Int. Ed., 2007, 46, 5583–5586; (i) A. Correa,
M. Carril and C. Bolm, Angew. Chem., Int. Ed., 2008, 47,
2880–2883; ( j) S. L. Buchwald and C. Bolm, Angew. Chem.,
Int. Ed., 2009, 48, 5586–5587.
Notes and references
1 (a) A. Ricci, Amino Group Chemistry From Synthesis to the
Life Sciences, Wiley-VCH, Weinheim, 2008; (b) A. J. Fatiadi,
S. Patai and Z. Ed. Rappaport, in Preparation and Synthetic
Applications of CyanoCompounds, Wiley, NewYork, 1983;
(c) A. Kleemann, A. Engel, B. Kutscher and D. Reichert,
Pharmaceutical sustance: Synthesis Patents, Applications,
Georg Thieme, Stuttgart, 4th edn, 2001.
2 (a) S. R. Sandler and W. Karo in Organic Functional Group
Preparations, Academic, New York, 1972, vol. 3; (b) S. R.
Sandler and W. Karo in Organic Functional Group Preparations,
Academic, New York, 1972, vol. 2; (c) A. Nickon and L. F. Fieser,
J. Am. Chem. Soc., 1952, 74, 55–66; (d) Q. Jia, T. Cai,
L. M. H. Haung, M. Xian, T. L. Poulos and P. G. Wang, J. Med.
Chem., 2003, 46, 2271; (e) T. Cai, M. Xian and P. G. Wang,
Bioorg. Med. Chem. Lett., 2002, 12, 1507; ( f ) V. Kumar, M. P.
8 (a) T. Ramana, P. Saha, M. Das and T. Punniyamurthy, Org.
Lett., 2010, 12, 84; (b) S. K. Sahoo, L. Jamir, S. Guin and
B. K. Patel, Adv. Synth. Catal., 2010, 352, 2538.
9 (a) H. Fadrus and J. Mal´y, Analyst, 1975, 100, 549;
(b) A. Neumann, T. L. Olson and M. Scherer, Environ. Sci.
Technol., 2013, 47, 6969.
Kaushik and A. Mazumdar, Eur. J. Org. Chem., 2008, 1910; 10 (a) A. Fu¨rstner and R. Martin, Chem. Lett., 2005, 34, 624;
(g) M. Saneyoshi, R. Tokuzen, M. Maeda and F. Fukuoka,
Chem. Pharm. Bull., 1968, 16, 505; (h) A. G. Gilman, L. S.
Goodman, T. W. Rall and F. Murad, Goodman and Gilman’s
The Pharmacological Basis of Therapeutics, Pergmon Press,
New York, 7th edn, 1990; (i) J. L. La Mattina, J. Heterocycl.
Chem., 1983, 20, 533.
(b) C. Bolm, J. Legros, J. Le Paih and L. Zani, Chem. Rev.,
¨
2004, 104, 6217; (c) I. Bauer and H.-J. Knolker, Chem. Rev.,
2015, 115, 3170; (d) R. B. Bedford, Acc. Chem. Res., 2015,
48, 1485; (e) C. Cassani, G. Bergonzini and C.-J. Wallentin,
ACS Catal., 2016, 6, 1640; ( f ) T. L. Mako and J. A. Byers,
Inorg. Chem. Front., 2016, 3, 766.
This journal is ©The Royal Society of Chemistry and the Centre National de la Recherche Scientifique 2017
New J. Chem., 2017, 41, 8711--8713 | 8713